Aptar nasal system delivers FDA-approved heart rhythm drug CARDAMYST

Aptar Group Inc. (NYSE: ATR) announced that its Bidose nasal spray system delivers CARDAMYST (etripamil), which received U.S. Food and Drug Administration approval for treating paroxysmal supraventricular tachycardia in adults.

CARDAMYST, developed by Milestone Pharmaceuticals Inc. (NASDAQ: MIST), is designed to convert acute symptomatic episodes of PSVT to normal heart rhythm. The condition affects an estimated two million people in the United States and causes 140,000 to 525,000 emergency department visits annually.

PSVT is characterized by sudden rapid heartbeats often exceeding 150 to 200 beats per minute. The condition results in 40,000 to 120,000 inpatient hospitalizations in the U.S. each year, according to the press release.

The treatment uses Aptar's dual Bidose delivery system housed in a protective two-pack container developed in collaboration with Aptar CSP Technologies. The container system is designed to prevent accidental activation and secure the delivery mechanisms.

"This approval underscores the broadening of Aptar's drug delivery solutions for more therapeutic areas and the growing demand for nasal drug delivery," said Gael Touya, President of Aptar Pharma.

Joseph Oliveto, President and CEO of Milestone Pharmaceuticals, stated that Aptar "has been an essential partner in developing and delivering a novel treatment for PSVT that fills a serious unmet need."

This represents the first combination of dual Bidose delivery systems in a consumer-friendly protective container for Aptar. The company's Bidose and Unidose systems are designed for single or two-shot intranasal delivery of various medicines.

Aptar is headquartered in Crystal Lake, Illinois, and has over 13,000 employees in 20 countries. The company provides drug and consumer product dosing, dispensing and protection technologies across pharmaceutical, beauty, food, beverage, personal care and home care markets.

You May Also Be Interested In

• Barclays Upgrades 1&1 AG (1U1:GR) to Overweight
• Passage Bio and Remix Therapeutics agree to all-stock merger deal
• EU approves Merck's Keytruda plus Padcev for bladder cancer